Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Infect Immun ; 76(2): 820-7, 2008 Feb.
Article in English | MEDLINE | ID: mdl-18039838

ABSTRACT

The opportunistic human pathogenic fungus Aspergillus fumigatus causes severe systemic infections and is a major cause of fungal infections in immunocompromised patients. A. fumigatus conidia activate the alternative pathway of the complement system. In order to assess the mechanisms by which A. fumigatus evades the activated complement system, we analyzed the binding of host complement regulators to A. fumigatus. The binding of factor H and factor H-like protein 1 (FHL-1) from human sera to A. fumigatus conidia was shown by adsorption assays and immunostaining. In addition, factor H-related protein 1 (FHR-1) bound to conidia. Adsorption assays with recombinant factor H mutants were used to localize the binding domains. One binding region was identified within N-terminal short consensus repeats (SCRs) 1 to 7 and a second one within C-terminal SCR 20. Plasminogen was identified as the fourth host regulatory molecule that binds to A. fumigatus conidia. In contrast to conidia, other developmental stages of A. fumigatus, like swollen conidia or hyphae, did not bind to factor H, FHR-1, FHL-1, and plasminogen, thus indicating the developmentally regulated expression of A. fumigatus surface ligands. Both factor H and plasminogen maintained regulating activity when they were bound to the conidial surface. Bound factor H acted as a cofactor to the factor I-mediated cleavage of C3b. Plasminogen showed proteolytic activity when activated to plasmin by urokinase-type plasminogen activator. These data show that A. fumigatus conidia bind to complement regulators, and these bound host regulators may contribute to evasion of a host complement attack.


Subject(s)
Aspergillus fumigatus/immunology , Complement System Proteins/immunology , Complement System Proteins/metabolism , Binding Sites , Blood Proteins/immunology , Blood Proteins/metabolism , Complement C3b Inactivator Proteins , Complement Factor H/immunology , Complement Factor H/metabolism , Humans , Plasminogen/immunology , Plasminogen/metabolism , Protein Binding , Protein Interaction Mapping , Spores, Fungal/immunology
2.
J Control Release ; 112(3): 369-81, 2006 May 30.
Article in English | MEDLINE | ID: mdl-16644054

ABSTRACT

The purpose of this study was to design microspheres combining sustained delivery and enhanced intracellular penetration for ocular administration of antisense oligonucleotides. Nanosized complexes of antisense TGF-beta2 phosphorothioate oligonucleotides (PS-ODN) with polyethylenimine (PEI), and naked PS-ODN were encapsulated into poly(lactide-co-glycolide) microspheres prepared by the double-emulsion solvent evaporation method. The PS-ODN was introduced either naked or complexed in the inner aqueous phase of the first emulsion. We observed a marked influence of microsphere composition on porosity, size distribution and PS-ODN encapsulation efficiency. Mainly, the presence of PEI induced the formation of large pores observed onto microsphere surface. Introduction of NaCl in the outer aqueous phase increased the encapsulation efficiency and reduced microsphere porosity. In vitro release kinetic of PS-ODN was also investigated. Clearly, the higher the porosity, the faster was the release and the higher was the burst effect. Using an analytical solution of Fick's second law of diffusion, it was shown that the early phase of PS-ODN and PS-ODN-PEI complex release was primarily controlled by pure diffusion, irrespectively of the type of microsphere. Finally, microspheres containing antisense TGF-beta2 nanosized complexes were shown, after subconjunctival administration to rabbit, to significantly increase intracellular penetration of ODN in conjunctival cells and subsequently to improve bleb survival in a rabbit experimental model of filtering surgery. These results open up interesting prospective for the local controlled delivery of genetic material into the eye.


Subject(s)
Glaucoma/drug therapy , Glaucoma/surgery , Nanostructures , Oligonucleotides, Antisense/administration & dosage , Polyethyleneimine/administration & dosage , Thionucleotides/administration & dosage , Transforming Growth Factor beta/administration & dosage , Animals , Conjunctiva/drug effects , Delayed-Action Preparations/administration & dosage , Female , Oligonucleotides, Antisense/pharmacokinetics , Rabbits , Thionucleotides/pharmacokinetics , Transforming Growth Factor beta/genetics , Transforming Growth Factor beta/pharmacokinetics , Transforming Growth Factor beta2
SELECTION OF CITATIONS
SEARCH DETAIL
...